Publicaciones en colaboración con investigadores/as de University of Groningen (68)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

  2. Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 3, pp. 374-387

  3. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

    Infection

  4. RhoA downregulation in the murine intestinal epithelium results in chronic Wnt activation and increased tumorigenesis

    iScience, Vol. 27, Núm. 4

  5. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry

    Hematological Oncology, Vol. 42, Núm. 1

  6. Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation

    Journal of Infectious Diseases, Vol. 229, Núm. 1, pp. 83-94

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

    International Journal of Infectious Diseases, Vol. 137, pp. 98-110

  3. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  4. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 6, pp. 1706-1717

  5. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

    Blood Advances, Vol. 7, Núm. 11, pp. 2645-2655

2022

  1. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

    Blood, Vol. 140, Núm. 26, pp. 2773-2787

  2. Changes in Right Ventricular–to–Pulmonary Artery Coupling After Transcatheter Edge-to-Edge Repair in Secondary Mitral Regurgitation

    JACC: Cardiovascular Imaging, Vol. 15, Núm. 12, pp. 2038-2047

  3. Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality

    European Journal of Heart Failure, Vol. 24, Núm. 11, pp. 2175-2184

  4. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950

  5. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Leukemia, Vol. 36, Núm. 5, pp. 1371-1376

  6. Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2039-2051

  7. Myosin Vb as a tumor suppressor gene in intestinal cancer

    Oncogene, Vol. 41, Núm. 49, pp. 5279-5288

  8. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

    American Journal of Hematology

  9. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2025-2038.e1